In recent years, some new positron emission tomography (PET) radiopharmaceuticals have come to attention as possible alternatives to fluorine-18-fluoro-2-deoxyglucose (18F-FDG) PET. In this context, this chapter describes the role of PET with gallium-68 (68Ga)-Pentixafor, describing potential clinical indications, with interesting clinical cases. Moreover, synthesis, pharmacokinetics and physiological distribution of 68Ga-Pentixafor, and PET acquisition protocols are described as well.
68Ga-Pentixafor / Russo, Francesca; Menichini, Massimo; Ricci, Maria; Travascio, Laura; Dadgar, Habibollah; Arabi, Hossein; Norouzbeigi, Nasim; De Feo, Maria Silvia; Zaidi, Habib; Albalooshi, Batool; Cimini, Andrea. - (2024), pp. 287-296. [10.1007/978-3-031-54196-4_17].
68Ga-Pentixafor
De Feo, Maria Silvia;
2024
Abstract
In recent years, some new positron emission tomography (PET) radiopharmaceuticals have come to attention as possible alternatives to fluorine-18-fluoro-2-deoxyglucose (18F-FDG) PET. In this context, this chapter describes the role of PET with gallium-68 (68Ga)-Pentixafor, describing potential clinical indications, with interesting clinical cases. Moreover, synthesis, pharmacokinetics and physiological distribution of 68Ga-Pentixafor, and PET acquisition protocols are described as well.| File | Dimensione | Formato | |
|---|---|---|---|
|
68Ga-Pentixafor.pdf
solo gestori archivio
Note: Russo_68Ga-Pentixafor_2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
273.59 kB
Formato
Adobe PDF
|
273.59 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
